Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.
In the past week, Evaxion announced promising phase I data for its cancer vaccine, several companies presented their first quarter results and some got their price targets updated.
10 of the 20 listed, Danish biotech companies have published news the past week. Only 6 of the 20 companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Curasight has become the best performing stock this year.
Company news the past week
Ascendis Pharma
Ascendis Pharma to Host Oncology Program Update on May 31 (Link)
No news the past week
Cessatech
No news the past week
CS MEDICA Onboards distributors with first-year orders of DKK 5.6M and cash flow positively effect by shorter lead times (Link)
Curasight: Interim report Q1 2023 (Link)
Evaxion Biotech
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01 (Link)
Expres2ion
No news the past week
Fluoguide
FluoGuide awarded prestigious grant together with two academic partners (Link)
FluoGuide provides update on strong clinical trial progress (Link)
Genmab
Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress (Link)
Gubra
No news the past week
Initiator Pharma
No news the past week
IO Biotech
Jefferies raises price target to $12 from $10
Pila Pharma
No news the past week
Saniona
Saniona publishes its interim report for the first quarter of 2023 (Link)
Scandion Oncology
SCANDION ONCOLOGY – INTERIM REPORT Q1 2023 (Link)
SynAct Pharma
No news the past week
ViroGates
No news the past week
Zealand Pharma
No news the past week
Y-mAbs Therapeutics
Y-mAbs’ Danyelza (naxitamab-gqgk) For Treatment Of High-Risk Neuroblastoma Approved In Brazil (Link)
2cureX
2cureX publishes interim report for the first quarter of 2023 (Link)
SELECTED CASES
SHARE PRICE DEVELOPMENTS
The majority of the Danish Biotech stocks delivered a negative share price performance last week. The average return was -2%. Curasight rose 21% following its Q1 report. Pila Pharma AB also performed well with 11% increase without presenting any news. On the other hand, Saniona AB, Biosergen AB, Cessatech A/S, and Y-mAbs Therapeutics Inc. all fell by more than 10%. Year to date a few companies have delivered excellent returns. Curasight A/S, Fluoguide A/S and Saniona AB have risen by 89-140% after among other things partnerships and positive recommendations paving the way for approvals.
Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment
Overview of share price developments the past week, year-to-date and last twelve months
